Volltext-Downloads (blau) und Frontdoor-Views (grau)

R&D efficiency of leading pharmaceutical companies — a 20-year analysis

  • Comparative analysis of the R&D efficiency of 14 leading pharmaceutical companies for the years 1999–2018 shows that there is a close positive correlation between R&D spending and the two investigated R&D output parameters, approved NMEs and the cumulative impact factor of their publications. In other words, higher R&D investments (input) were associated with higher R&D output. Second, our analyses indicate that there are ‘economies of scale’ (size) in pharmaceutical R&D.

Download full text files

  • 3183
    eng

Export metadata

Additional Services

Share in Twitter Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author of HS ReutlingenKandelbauer, Andreas
DOI:https://doi.org/10.1016/j.drudis.2021.05.005
ISSN:1359-6446
Erschienen in:Drug discovery today
Publisher:Elsevier Science
Place of publication:Amsterdam
Document Type:Article
Language:English
Year of Publication:2021
Tag:R&D efficiency; big pharma; economies of scale; pharmaceutical R&D
Volume:26
Issue:8
Page Number:6
First Page:1784
Last Page:1789
DDC classes:610 Medizin und Gesundheit
Open Access?:Nein
Licence (German):License Logo  Lizenzbedingungen Elsevier